Search tips
Search criteria 


Logo of cviPermissionsJournals.ASM.orgJournalAEM ArticleJournal InfoAuthorsReviewers
Clin Vaccine Immunol. 2010 April; 17(4): 688–690.
Published online 2010 February 10. doi:  10.1128/CVI.00433-09
PMCID: PMC2849343

Promising Rabies Vaccine for Postexposure Prophylaxis in Developing Countries, a Purified Vero Cell Vaccine Produced in China[down-pointing small open triangle]


We evaluated the immunogenicity, safety, and antibody persistence of a Vero cell rabies vaccine manufactured in China, compared with those of Verorab. Adequate titers of antibody were observed for the two vaccines. ChengDa rabies vaccine could be a promising alternative vaccine for many developing countries which cannot afford expensive rabies vaccines.

Although effective rabies vaccines for postexposure treatment are available (3), there are still about 50,000 to 60,000 human deaths annually. China, as the largest developing country in the world, has endeavored tremendously in rabies prevention and vaccine manufacturing. China accounts for almost two-thirds of the total rabies vaccines used in Asia (9), with the locally produced tissue culture vaccine being safe and relatively inexpensive (5). Currently, the most common rabies vaccine used in China is purified Vero cell vaccine, referred to as ChengDa (Liaoning ChengDa Biological Co., Ltd., Shengyang, China). ChengDa rabies vaccine is grown on a Vero cell line utilizing the L. Pasteur 2061 strain of rabies virus. It is inactivated with β-propiolactone (BPL), lyophilized, and reconstituted in 0.5 ml of physiological saline. It is manufactured according to good manufacturing practices (GMP) and strictly fulfills the WHO recommendations for potency (8). ChengDa was licensed by the Health Ministry of China and the State Food and Drug Administration of China (SFDA) in 2002 and has been marketed throughout the country since that time.

This study was designed to compare the immunogenicity, safety, and persistence of the two different Vero cell rabies vaccines (ChengDa and Verorab) available in China. The study was conducted in the Emergency Department, Beijing University People's Hospital, and the antibody evaluation was performed primarily at the National Institute for the Control of Pharmaceutical and Biological Products. Formal ethical approval was obtained from the ethics committee of Beijing University People's Hospital. Written informed consent was obtained from each subject and/or his/her legal representative. Intramuscular doses of either 0.5 ml of ChengDa or 0.5 ml of Verorab were given to 500 patients on days 0, 3, 7, 14, and 28. Blood samples from all vaccinees were taken on days 0, 7, 14, 45, and 365. Antibody testing was performed using the rapid fluorescent focus inhibition test (RFFIT) in 96-well microplates according to the technique of Zalan et al. (10).

From February 2006 to September 2008, a total of 500 patients with WHO-designated category I or II rabies exposure were enrolled and randomly assigned to the ChengDa group or the Verorab group. A study flow chart is shown in Fig. Fig.1.1. The baseline demographic characteristics are demonstrated in Table Table1,1, and subjects were similarly distributed in the two groups. The exclusion criteria included poor compliance, primary or acquired immunodeficiency, corticosteroid intake, and previous rabies immunization. Rabid patients and patients who were simultaneously in other clinical trials were also excluded.

FIG. 1.
Study flow chart.
Baseline demographic characteristics of subjects

ChengDa rabies vaccine, lot numbers 20060123-20070213 and 20080712-20080810, with a registered potency of 4.5 IU/0.5 ml, and Verorab, lot numbers D0033-1-D0043-1 and Z0096-2, with a registered potency of 3.1I U/0.5 ml, were used. The Essen intramuscular regimen was adopted in this study (7). SPSS 11.5 was used for statistical analysis, and a P value of <0.05 was considered significant. The chi-square test was used for the comparison of adverse reaction rates.

Overall, only 46 local reactions were reported for 34 subjects (13.6%) in the ChengDa group, and 41 reactions were reported for 32 subjects (12.8%) in the Verorab group. No significant differences were observed in adverse reaction rates between the two groups (chi-square value = 0.348, P > 0.05). The details are shown in Table Table2.2. From day 14, all patients in both groups had levels of neutralizing antibody to rabies virus in excess of adequate titers (>0.5 IU/ml) as defined by the WHO, and data on immunogenicity and persistence are shown in Table Table33.

Adverse reaction summarya
Geometric mean titers of serum neutralizing antibodies in patients after primary postexposure immunization with ChengDa or Verorab rabies vaccine

ChengDa rabies vaccine offers an alternative with a high degree of efficacy and yet limited side effects, similar to Verorab, and ensures that the exposed patient will be on the safe side of the rabies risk by the 14th day at the latest and probably sooner; however, the price of ChengDa rabies vaccine is almost half of that of Verorab.

In most of the developing countries, modern cell culture vaccines are too costly for the poorly developed remote regions, and so dangerous nerve tissue vaccines (NTVs) are still used (1, 2). Therefore, there is an urgent requirement for effective and cheap rabies vaccines worldwide, especially in the developing countries (4, 6). Good efficacy and tolerance, early induction of antibody response, and long-term persistence of protective antibody titer, in addition to more than 5 years of clinical use experience, make ChengDa a promising vaccine for postexposure treatment of rabies worldwide. ChengDa is currently used in China and India, as well as in the regions of Asia, Africa, and the Americas where rabies is endemic.


This study was supported by the research and development funds from our emergency department.

We specially thank our colleagues from the emergency department of Beijing University People's Hospital and the doctors in surgery training for their support.

We, all the authors of this paper, hereby state that we do not have any conflicts of interest with other people or organizations that could inappropriately influence this work.


[down-pointing small open triangle]Published ahead of print on 10 February 2010.


1. Cleaveland, S., M. Kaare, D. Knobel, and M. K. Laurenson. 2006. Canine vaccination—providing broader benefits for disease control. Vet. Microbiol. 117:43-50. [PubMed]
2. Coulibaly, N. D., and K. R. Yameogo. 2000. Prevalence and control of zoonotic diseases: collaboration between public health workers and veterinarians in Burkina Faso. Acta Trop. 76:53-57. [PubMed]
3. Dodet, B. 2006. Preventing the incurable: Asian rabies experts advocate rabies control. Vaccine 24:3045-3049. [PubMed]
4. Kihm, U., A. Flamand, P. P. Pastoret, and E. Peterhans. 1992. Round table on epidemiology and control of fox rabies. Vet. Microbiol. 33:297-301. [PubMed]
5. Lin, F. T., and N. Lina. 2000. Developments in the production and application of rabies vaccine for human use in China. Trop. Doct. 30:14-16. [PubMed]
6. Slater, M. R. 2001. The role of veterinary epidemiology in the study of free-roaming dogs and cats. Prev. Vet. Med. 48:273-286. [PubMed]
7. WHO. 2009. Current WHO guide for rabies pre and post exposure treatment in humans. World Health Organization Division of Emerging and Other Communicable Diseases Surveillance and Control, Geneva, Switzerland.
8. WHO. 1992. WHO Expert Committee on Rabies, 8th report. World Health Organ. Tech. Rep. Ser. 824:1-84. [PubMed]
9. WHO. 1999. World survey of rabies no. 34 for the year 1998. WHO document CSR/APH/99.6. World Health Organization, Geneva, Switzerland.
10. Zalan, E., C. Wilson, and D. Pukitis. 1979. A microtest for the quantitation of rabies virus neutralizing antibodies. J. Biol. Stand. 7:213-220. [PubMed]

Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of American Society for Microbiology (ASM)